Business
NRx Pharmaceuticals (Nasdaq:NRXP) Announces FDA Clearance to Proceed with Clinical Trial of NRX-101 in Combination with Robotic-enabled Transcranial Magnetic Stimulation in Patients with Depression and Suicidality
Preliminary research suggests that D-cycloserine significantly enhances the effect of Transcranial Magnetic Stimulation (TMS) Trial is planned to be conducted at a leading US academic teaching hospital, three HOPE Therapeutics Clinics, and two military treatment facilitiesCompany targeting non-dilutive funding to support enrollment of 400 patients Should the trial yield successful results, D-cycloserine-augmented TMS could play a significant role in the readiness of first responders, military pe
About this update from Nrx Pharmaceuticals, Inc.
[{"type":"image","alt":"NRx Pharmaceuticals, Inc.","displaySize":"","headline":null,"caption":"NRx Pharmaceuticals, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":300,"url":"https://media.zenfs.com/en/globenewswire.com/4ef53875d129fcc14f2614dd5795d5a9"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/oQlnKXAw77IR4.RQxkfHUQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTQyMA--/https://media.zenfs.com/en/globenewswire.com/4ef53875d129fcc14f2614dd5795d5a9","width":300,"height":300},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/oQlnKXAw77IR4.RQxkfHUQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTQyMA--/https://media.zenfs.com/en/globenewswire.com/4ef53875d129fcc14f2614dd5795d5a9","width":300,"height":300}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Preliminary research suggests that D-cycloserine significantly enhances the effect of Transcranial Magnetic Stimulation (TMS) Trial is planned to be conducted at a leading US academic teaching hospital, three HOPE Therapeutics Clinics, and two military treatment facilities","length":273,"tagName":"p"}]},{"val":[{"type":"text","content":"Company targeting non-dilutive funding to support enrollment of 400 patients","length":76,"tagName":"p"}]},{"val":[{"type":"text","content":"Should the trial yield successful results, D-cycloserine-augmented TMS could play a significant role in the readiness of first responders, military personnel, and others affected by Treatment-resistant Depression","length":212,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":561,"olType":false},{"type":"text","content":"WILMINGTON, Del., May 07, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals (Nasdaq:NRXP) announces receipt of clearance from the US Food and Drug Administration to initiate a clinical trial of NRX-101 (D-cycloserine/lurasidone fixed dose combination) vs. placebo in patients with depression and suicidality who are being treated with either Robotic-assisted Transcranial Magnetic Stimulation (TMS) or sham TMS. The placebo-controlled phase 2/3 trial is identified as “A Randomized, Double-Blind, Three-Arm Study of NRX-101 as Adjunctive Therapy to Active or Sham Transcranial Magnetic Stimulation in Adults with Treatment Resistant Major Depressive Disorder (MIND1).","length":662,"tagName":"p"},{"type":"text","content":"The trial will be conducted by NRx Defense Sys...